Strike action is taking place from 7am on Tuesday, 7 April to 7am on Monday, 13 April 2026. Please continue to attend appointments as usual. We'll contact you directly if your care is affected to rearrange your appointment as quickly as possible.
What is the study about?
TargetTau is a clinical trial looking at whether a new drug can slow the progression of Alzheimer’s disease. Our Trust is the first centre in England to offer an opportunity to take part in this trial, which is sponsored by the biopharmaceutical company Bristol Myers Squibb. Spaces for participants are very limited.
What is involved?
The study includes an 8-week screening period followed by a 76-week double-blind treatment phase, during which participants will receive either the active drug, BMS-986446, or a placebo. At the end of the Phase II trial, all participants may have the opportunity to join an extended study where everyone receives the new drug.
Who can take part?
We are looking for participants aged 50-80 years who have a diagnosis of mild cognitive impairment or early Alzheimer’s disease. Participants must also weigh 70kg-120kg.
Help us improve our website
Please take a moment to share your thoughts and help us enhance our website by completing our short survey here.